ophthalmology 

 
 

With the expected changes in demographics over the next 10-15 years, there is a growing need to increase and accelerate the development of safe and effective therapies for eye disorders. Charles River has the necessary understanding of eye-related diseases and conditions as well as the technical ability and experience to guide your new drugs and treatments through the development process as efficiently as possible. 

Through our Preclinical, Clinical, and Research Models products and services groups, we offer you an integrated approach to ophthalmology research. Compounds or implantable devices intended for ocular treatment can be assessed for efficacy, safety, and toxicity. In addition, ocular effects of compounds targeted to non-ocular conditions can also be characterized. 

For more information please call:

877.CRIVER.1 (US & Canada) 888.319.5343 (Worldwide)

view all

News & Events

view all
Nov 05 Charles River Announces Third-Quar...
Oct 30 Charles River Adds Veterinary Scho...
Dec 01-Dec 03 Kyoto, Japan 38th Annual Meeting of the Japanese Society for Immunolo...
Nov 25-Nov 26 Basel, Switzerland SGV Continuing Education Meeting 2008
Dec 10-Dec 10 Shrewsbury, MA Making Sense of Biotech Funding Strategies in Today’s ...